These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21476105)

  • 21. Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)?
    Benveniste AP; Ortiz-Perez T; Ebuoma LO; Sepulveda KA; Severs FJ; Roark A; Wang T; Sedgwick EL
    Eur J Radiol; 2017 Nov; 96():74-79. PubMed ID: 29103479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.
    Moore KH; Sweeney KJ; Wilson ME; Goldberg JI; Buchanan CL; Tan LK; Liberman L; Turner RR; Lagios MD; Cody Iii HS; Giuliano AE; Silverstein MJ; Van Zee KJ
    Ann Surg Oncol; 2007 Oct; 14(10):2911-7. PubMed ID: 17597346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study.
    Lopez Gordo S; Blanch Falp J; Lopez-Gordo E; Just Roig E; Encinas Mendez J; Seco Calvo J
    Int J Surg; 2019 Mar; 63():98-106. PubMed ID: 30738200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
    Butt S; Butt T; Jirström K; Hartman L; Amini RM; Zhou W; Wärnberg F; Borgquist S
    Ann Surg Oncol; 2014 Sep; 21(9):2911-9. PubMed ID: 24777857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.
    Solin LJ; Gray R; Hughes LL; Wood WC; Lowen MA; Badve SS; Baehner FL; Ingle JN; Perez EA; Recht A; Sparano JA; Davidson NE
    J Clin Oncol; 2015 Nov; 33(33):3938-44. PubMed ID: 26371148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study.
    Vidali C; Caffo O; Aristei C; Bertoni F; Bonetta A; Guenzi M; Iotti C; Leonardi MC; Mussari S; Neri S; Pietta N
    Radiat Oncol; 2012 Oct; 7():177. PubMed ID: 23098066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.
    Padmore RF; Fowble B; Hoffman J; Rosser C; Hanlon A; Patchefsky AS
    Cancer; 2000 Mar; 88(6):1403-9. PubMed ID: 10717623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge.
    Cabioglu N; Krishnamurthy S; Kuerer HM; Hunt KK; Singletary SE; Meric-Bernstam F; Ross MI; Feig BW; Ames FC; Babiera GV
    Cancer; 2004 Aug; 101(3):508-17. PubMed ID: 15274063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.
    Kerlikowske K; Molinaro A; Cha I; Ljung BM; Ernster VL; Stewart K; Chew K; Moore DH; Waldman F
    J Natl Cancer Inst; 2003 Nov; 95(22):1692-702. PubMed ID: 14625260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ.
    Greenberg CC; Habel LA; Hughes ME; Nekhlyudov L; Achacoso N; Acton L; Schrag D; Jiang W; Edge S; Weeks JC; Punglia RS
    Ann Surg Oncol; 2014 Nov; 21(12):3766-73. PubMed ID: 24859938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes in patients treated with mastectomy for ductal carcinoma in situ.
    Owen D; Tyldesley S; Alexander C; Speers C; Truong P; Nichol A; Wai ES
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e129-34. PubMed ID: 23195778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
    Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
    J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperatively diagnosed ductal cancers in situ of the breast presenting as even small masses are of high risk for the invasive cancer foci in postoperative specimen.
    Szynglarewicz B; Kasprzak P; Halon A; Matkowski R
    World J Surg Oncol; 2015 Jul; 13():218. PubMed ID: 26179898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall survival is improved when DCIS accompanies invasive breast cancer.
    Kole AJ; Park HS; Johnson SB; Kelly JR; Moran MS; Patel AA
    Sci Rep; 2019 Jul; 9(1):9934. PubMed ID: 31289308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of screening-detected ductal carcinoma in situ treated with wide excision alone.
    Fong J; Kurniawan ED; Rose AK; Mou A; Collins JP; Miller JA; Mann GB
    Ann Surg Oncol; 2011 Dec; 18(13):3778-84. PubMed ID: 21630124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy.
    Kotani H; Yoshimura A; Adachi Y; Ishiguro J; Hisada T; Ichikawa M; Gondou N; Hattori M; Kondou N; Sawaki M; Fujita T; Iwata H
    Breast Cancer; 2016 Mar; 23(2):190-4. PubMed ID: 24989112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.